期刊
ADVANCED BIOLOGY
卷 6, 期 2, 页码 -出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/adbi.202101133
关键词
cardiac hypertrophy; cardiomyogenesis; heart failure; regeneration
资金
- National Institutes of Health [R01 HL123920, HL137093, HL144002, HL146153, HL154154, HL147357]
- American Heart Association [19EIA34660286, 21CDA855570]
Heart failure is a leading cause of hospital admissions worldwide, with patients classified based on left ventricular ejection fraction changes. Current treatments can prevent one type of heart failure from progressing, but few have been shown to improve survival in another type.
Heart failure (HF) is one of the leading causes for hospital admissions worldwide. HF patients are classified based on the chronic changes in left ventricular ejection fraction (LVEF) as preserved (LVEF >= 50%), reduced (LVEF <= 40%), or mid-ranged (40% < LVEF < 50%) HFs. Treatments nowadays can prevent HFrEF progress, whereas only a few of the treatments have been proven to be effective in improving the survival of HFpEF. In this review, numerous mediators involved in the pathogenesis of HF are summarized. The regional upstream signaling and their diagnostic and therapeutic potential are also discussed. Additionally, the recent challenges and development in cardiac regenerative therapy that hold opportunities for future research and clinical translation are discussed.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据